ライフサイエンスコーパス: VT

1 VT correlated better with SUVRWM (Pearson r: from 0.63 f

2 VT did not differ between patients who did and did not d

3 VT recurrence post ablation is associated with a mortali

4 VT values in brain regions correlated well with mGluR1 t

5 VT values were obtained from different compartment model

6 VT was greater in mild cognitive impairment subjects tha

7 VT was high ( approximately 25-55 mL/cm(3)) in all gray

8 ter the last procedure, 91% experienced >/=1 VT recurrence, 44% received or were awaiting mechanical

9 of 850 days (interquartile range, 439-1707), VT recurrence was observed in 36%.

10 irtual taxa (VT) were detected, including 22 VT new to science.

11 31 (53%) patients having only isolated (1-3) VT episodes in 12 (4-35) months after the procedure.

12 llation number of intervals to detect=24/32, VT number of intervals to detect>/=16, and a fast VT zon

13 A total of 44 VT ablation procedures were performed in 41 patients (22

14 In initial mapping stage (16 patients and 58 VTs), left ventricular endocardial mapping was performed

15 analysis with arterial input function gave a VT highly consistent with VT in the kinetic model, which

16 ients but none of the group B patients had a VT recurrence.

17 as associated with greater PFC and ACC MAO-A VT compared with moderate BPD, MDE, and healthy control

18 r = .38, p = .046), while hippocampus MAO-A VT was negatively correlated with verbal memory (r = -.4

19 In BPD, PFC and ACC MAO-A VT were positively correlated with mood symptoms (PFC: r

20 The finding of a VT on MRI imaging of the lumbar spine is often incidenta

21 Before ablation, VT was inducible in 75%, and endocardial/epicardial LAVA

22 an be used to obtain quantitatively accurate VT images of (18)F-DPA-714.

23 nd PCI in 407974 patients hospitalized after VT/VF OHCA from January 1, 2000, through December 31, 20

24 to 2012, coronary angiography and PCI after VT/VF OHCA increased in patients with STE (53.7% to 87.2

25 fidence interval [CI] = 90.22-98.32) against VT HPV and 38.37% (95% CI = 12.68-56.51) against cross-r

26 with nonischemic dilated cardiomyopathy and VT, endocardial and adjuvant epicardial CA is effective

27 We compared characteristics and VT radiofrequency ablation outcomes of those with and wi

28 implantable cardioverter-defibrillator, and VT storm despite greater antiarrhythmic drug use (P<0.01

29 se mechanisms by which differences in fR and VT are mediated.

30 entative evidence that the pattern of fR and VT could provide some useful diagnostic information for

31 is an overall differential control of fR and VT that applies in a wide range of conditions.

32 ain and panic on the contributions of fR and VT to VE to see if they differ with different stressors.

33 ability was determined for parametric K1 and VT values.

34 ations between IDIF- and BSIF-derived K1 and VT were high (r(2) > =0.89 for 3DR and TF).

35 minated AES leading to ECG normalization and VT/VF noninducibility in all patients.

36 AES leading to ECG pattern normalization and VT/VF noninducibility.

37 cy ablation results in ECG normalization and VT/VF noninducibility.

38 weakest inhibitor, whereas posaconazole and VT-1161 were the strongest CYP51 inhibitors.

39 bicans CYP51 complexes with posaconazole and VT-1161, providing a molecular mechanism for the potenci

40 ithout arterial input function (refDVR), and VT Additional voxelwise SUVR group analyses were perform

41 ntable cardioverter-defibrillator shocks and VT episodes and improved quality of life at 6 months.

42 (18)F-AV45 VT was determined from 2-tissue-compartment modeling usi

43 SA-based VT images were most robust to increased noise on a voxel

44 Results:(11)C-BMT-136088 baseline VT was 1.83 +/- 0.16 (MA1, n = 5) or 2.1 +/- 0.55 (EA, n

45 s the reference region by comparing baseline VT with VT under full blocking conditions and comparing

46 We found that both VT Sync and Async conditions resulted in a strong subjec

47 doreference VT or SUV, excepting whole-brain VT, which was higher in cLBP patients than controls.

48 n (11)C-erlotinib distribution to the brain (VT, 0.81 +/- 0.21 mL/cm(3), P < 0.01), reaching levels c

49 more modern pipeline materials (Burlington, VT, and Indianapolis, IN).

50 le) and by a tetrazole-based drug candidate, VT-1161 (oteseconazole: (R)-2-(2,4-difluorophenyl)-1,1-d

51 ease in hippocampus, midbrain, or cerebellum VT Baseline striatal SRTM BPND did not differ significan

52 failure (persistent inducibility of clinical VT: 12.5%) was attributed to intramural septal substrate

53 The clinical VT was successfully ablated acutely in all patients.

54 Despite greater baseline comorbidities, VT radiofrequency ablation can be safely performed among

55 In contrast, VT or premature ventricular contractions in the setting

56 On follow-up of 590+/-722 days, VT recurred in 4 out of 7 patients, 3 of whom were succe

57 an LGE- (4.9 versus 0.2%, P<0.01); (2) death/VT were associated with a greater burden of LGE (14+/-11

58 The association between covariates and death/VT in the entire group and within the LGE+ group was det

59 LGE burden was the best predictor of death/VT (area under the receiver-operating characteristics cu

60 increase of LGE burden, the hazard of death/VT increased by 8%.

61 In the LGE+ group (1) the rate of death/VT per year was >20x higher than LGE- (4.9 versus 0.2%,

62 hat predict who is at greatest risk of death/VT.

63 ntify LGE+ patients at highest risk of death/VT.

64 p of 2.9 years, 254 (24%) patients developed VT/VF.

65 increased metoclopramide brain distribution (VT = 6.28 +/- 0.48 mLcm(-3)) with a 2.0-fold increase in

66 function with total volume of distribution (VT) as outcome measure.

67 netic modeling using volume of distribution (VT) as the outcome parameter.

68 Gray matter (GM) volume of distribution (VT) derived from a two-tissue compartmental analysis wit

69 btain the myocardial volume of distribution (VT) for (123)I-mIBG.

70 generate parametric volume of distribution (VT) images.

71 st the gold standard volume of distribution (VT) to assess cross-sectional differences in plaque load

72 egional tissue total volume of distribution (VT) was estimated by 1- and 2-tissue-compartment modelin

73 Total volume of distribution (VT) was estimated using compartmental modeling (1- and 2

74 The tracer volume of distribution (VT) was estimated using multilinear analysis 1 (MA1) or

75 Regional volume of distribution (VT) was estimated using the 1-tissue-compartment model.

76 to the brain (total volume of distribution [VT], 0.22 +/- 0.015 mL/cm(3)) was markedly lower than it

77 and electrophysiological information during VT ablation procedures.

78 Early VT recurrence (</=30 days) was significantly associated

79 Early VT recurrence is significantly associated with subsequen

80 e an alternative bail-out approach to failed VT RFA.

81 e and mortality were advanced heart failure, VT cycle length, and a left-sided-only procedure.

82 mber of intervals to detect>/=16, and a fast VT zone of 240 to 320 ms.

83 w tract scar serving as a substrate for fast VT in high-level endurance athletes that can be successf

84 justed) sustained monomorphic VT in the fast VT zone, 509 of 590 (85% adjusted) in the VT zone, and 6

85 ignificant correlations between [(18)F]FEPPA VT and duration of illness, clinical presentation, or ne

86 k of significant differences in [(18)F]FEPPA VT between groups suggests that microglial activation is

87 glial activation, as indexed by [(18)F]FEPPA VT, in either the dorsolateral prefrontal cortex or the

88 icular tachycardia-ventricular fibrillation (VT-VF).

89 quantitatively accurate parametric (18)F-FLT VT images in NSCLC patients before and during therapy.

90 quantitatively accurate parametric (18)F-FLT VT images in NSCLC patients before and during therapy.

91 vided incremental prognostic information for VT/VF over clinical and echocardiographic parameters (C

92 Abnormal SAECG after CA was a predictor for VT recurrence: hazard ratio=3.64; P=0.039 for the overal

93 The ICC values were higher for VTs than for brain SUVs, which were both moderate to hig

94 suggested, the arrhythmogenic substrate for VTs in athletes is unknown.

95 The outcome measure was VT/fP (VT is volume of distribution in region of interest, fP i

96 No correlation was observed between GM VT and clinical or cognitive measures after correction f

97 We describe a case of a slowly growing VT in a patient with progressing lower limb weakness wit

98 esent an intriguing case of a slowly growing VT in a woman with progressive neurological symptoms.

99 the setting of a structurally normal heart, VT that occurs in patients with structural heart disease

100 ropy mapping in the scar accurately identify VT channels during sinus rhythm.

101 Detailed pace mapping was used to identify VT channels and confirmed, when feasible, by entrainment

102 ation was robust and greatly reduced bias in VT (r(2) = 0.97, slope = 0.99) with no effect on K1 CONC

103 Biases in VT observed with all parametric methods were less than 5

104 of cases, with a substantial improvement in VT burden in many of the remaining patients.

105 No increase in VT with increased elacridar plasma exposure was found ov

106 significantly (1.7 +/- 0.2-fold) increased (VT, 0.38 +/- 0.033 mL/cm(3), P < 0.05), with a concomita

107 used SHR hearts revealed that H2 O2 -induced VT/VF arose spontaneously from focal activations at the

108 symptoms, and 72 (group 2) having inducible VT/VF without ECG documentation at the time of symptoms.

109 hannel regions eliminated 18 of 20 inducible VTs.

110 ith and without NYHA IV in the International VT Ablation Center Collaboration.

111 epending on their VT substrate: (1) ischemic VT (IVT) and (2) nonischemic VT and depending on the pre

112 s, ejection fraction 34+/-12%) with ischemic VTs were prospectively enrolled.

113 ar characteristics in patients with ischemic VTs.

114 ocardial scar size in patients with ischemic VTs.

115 aseline (11)C-metoclopramide brain kinetics (VT = 2.28 +/- 0.32 and 2.04 +/- 0.19 mLcm(-3) using micr

116 al class III and IV heart failure and longer VT cycle lengths were associated with recurrent ICD shoc

117 k Heart Association functional class, longer VT cycle lengths, and a left-sided-only procedure predic

118 e control subjects have shown relatively low VT, the methodology presented here forms the basis for q

119 ltivariate logistic regression analysis, LPF-VT was more often associated with atypical RBBB-like V1

120 urate tool for correctly differentiating LPF-VT from RBBB and LAHB aberrancy was developed.

121 variables had high probability of having LPF-VT, whereas patients with </=1 positive variable always

122 the morphological ECG characteristics of LPF-VT and attempt to differentiate it from RBBB and LAHB ab

123 Overall, 183 ECGs of LPF-VT were compared with 61 ECGs showing RBBB and LAHB.

124 The morphological ECG characteristics of LPF-VT were defined, and a high accurate tool for correctly

125 ction model was developed that predicted LPF-VT with sensitivity and specificity of 82.1% and 78.3%,

126 rior fascicular ventricular tachycardia (LPF-VT) is frequently misdiagnosed as supraventricular tachy

127 ECGs with LPF-VT were also collected from patients who underwent ablat

128 r locate ECG tracings from patients with LPF-VTs.

129 The majority of malignant VTs occur in patients with structural heart disease.

130 resystolic potentials and pace-maps matching VT/premature ventricular contraction.

131 9 of 69 (59% adjusted) sustained monomorphic VT in the fast VT zone, 509 of 590 (85% adjusted) in the

132 pisodes, including 669 sustained monomorphic VT, 20 polymorphic VT, 10 supraventricular tachycardia,

133 pisode, or a recorded, sustained monomorphic VT.

134 er, the serotype replacement observed in non-VT carriage is not paralleled in the incidence of OM due

135 paralleled in the incidence of OM due to non-VT pneumococcus.

136 rtial success (inducibility of a nonclinical VT only: 50%) and failure (persistent inducibility of cl

137 ed in 41 patients (22 IVT and 19 nonischemic VT).

138 e: (1) ischemic VT (IVT) and (2) nonischemic VT and depending on the presence of an epicardial access

139 tion exposure than patients with nonischemic VT (total fluoroscopy time, 2.53 [1.22-11.22] versus 8.5

140 ad the highest AMF richness, number of novel VT, and number of exclusive and indicator taxa.

141 anistically, we determined that the observed VT termination is due to ChR2-mediated transmural depola

142 e found a high turnover of AMF with < 12% of VT present in all vegetation types.

143 Catheter ablation of VT associated with LMNA cardiomyopathy is associated wit

144 es of these drugs, including the activity of VT-1161 against Candida krusei and Candida glabrata, pat

145 to determine the long-term outcome of CA of VT in patients with cardiac sarcoidosis.

146 (95% confidence interval) for the effect of VT recurrence occurring immediately post ablation on dea

147 ar by 30 min, yielding regional estimates of VT in excellent agreement with compartmental analysis an

148 1.2% to 26.8% (p < 0.0001); the frequency of VT in implantable cardioverter-defibrillator patients wi

149 cilitating the initiation and maintenance of VT due to less meandering rotor tip.

150 athophysiology, mechanism, and management of VT in the setting of structural heart disease and discus

151 athophysiology, mechanism, and management of VT that occurs in the setting of a structurally normal h

152 High-resolution activation mapping of VT may better guide ablation therapy.

153 is study, we identified a novel mechanism of VT resulted from enhanced repolarization dispersion whic

154 rovide a priori information on mechanisms of VT in patients undergoing interventional procedures.

155 aphic mapping to elucidate the mechanisms of VT.

156 al strain remained independent predictors of VT/VF (anterior: hazard ratio, 1.08 [1.03-1.13]; P=0.001

157 mong 18-26-year-old women, the prevalence of VT HPV decreased markedly over a short interval, from 15

158 agulation is one reason that the progress of VT is so much slower than that of arterial thrombosis in

159 still resulted in a significant reduction of VT burden, with 31 (53%) patients having only isolated (

160 ying etiology and prognostic significance of VT.

161 e useful to assess the procedural success of VT ablation.

162 issues, SUV is not a sufficient surrogate of VT from 2-tissue-compartment modeling.

163 However, the impact of the timing of VT recurrence on outcomes is unclear.

164 e interventional approaches for treatment of VT.

165 The mean TRT variabilities of VT and K1 were less than 10% for all methods.

166 premature ventricular contractions (PVCs) or VT and tachycardiomyopathy should be considered for abla

167 h SHD who underwent CSD for refractory VT or VT storm at 5 international centers were analyzed by the

168 he basis function method provided parametric VT and K1 values with the least bias compared with nonli

169 pants experienced synchronous (Sync) passive VT on their hands and abdomen, and the other half asynch

170 was a significant reduction of [(11)C]PBR28 VT in patients compared with healthy controls in GM as w

171 669 sustained monomorphic VT, 20 polymorphic VT, 10 supraventricular tachycardia, and 3 malsensing ep

172 on in the inferior myocardial wall predicted VT/VF (hazard ratio, 1.05 [1.00-1.11]; P=0.039).

173 Factors associated with prevalent VT in multivariable analysis were vaccine status, positi

174 H2 O2 promoted VT in all 30 SHR but none of the NR hearts.

175 ificant group differences in pseudoreference VT or SUV, excepting whole-brain VT, which was higher in

176 min scan duration was sufficient to quantify VT and the binding potentials.

177 In-hospital deaths, recurrent VT, and 1-year mortality were higher in the NYHA IV grou

178 e cardiac defibrillator shocks for recurrent VT/VF episodes.

179 Elimination of recurrent VT in NYHA IV patients may reduce mortality to a level c

180 with NYHA II and III patients with recurrent VT (68% versus 73%).

181 ortantly, NYHA IV patients without recurrent VT had similar survival compared with NYHA II and III pa

182 cy ablation has been associated with reduced VT recurrence and mortality, although it is typically no

183 In postinfarction reentrant VT, conduction velocities are slowest at the proximal an

184 correlated with VT and more closely reflects VT differences between aMCI and AD than SUVRCB.

185 ts with SHD who underwent CSD for refractory VT or VT storm at 5 international centers were analyzed

186 shock recurrence in patients with refractory VT.

187 erwent catheter ablation for infarct-related VT.

188 The cycle lengths of scar-related VTs were significantly faster in group B patients (257 +

189 emperature (1)H NMR spin-lattice relaxation (VT (1)H T1) data revealed rotational dynamics with indis

190 VTResults: During ABCB1 inhibition, retinal VT and influx rate constant K1 were significantly, by 1.

191 on volume VTDuring ABCB1 inhibition, retinal VT and influx rate constant K1 were significantly, by 1.

192 l, .28-.92), and the prevalence of high-risk VT HPV decreased from 13.1% to 6.5% (0.46; .25-.86).

193 the scan duration to 45 min provided similar VT and K1 with comparable TRT performance compared with

194 tion to muscle tissue surrounding the skull (VT, 0.86 +/- 0.10 mL/cm(3)).

195 support, were inducible for more and slower VTs, and were less likely to undergo final programmed st

196 =163) plus protective ventilation with small VT.

197 added to a protective ventilation with small VT.

198 Baseline striatal VT did not significantly differ between tracers.

199 te models for (18)F-FPSCH (baseline striatal VT, 3.7 +/- 1.1) and (18)F-FESCH (baseline striatal VT,

200 te models for (18)F-FPSCH (baseline striatal VT, 3.7 +/- 1.1) and (18)F-FESCH (baseline striatal VT,

201 +/- 1.1) and (18)F-FESCH (baseline striatal VT, 5.0 +/- 2.0), respectively.

202 +/- 1.1) and (18)F-FESCH (baseline striatal VT, 5.0 +/- 2.0), respectively.

203 After pretreatment, striatal VT was reduced significantly, with no significant decrea

204 n in 5 patients with left ventricular summit VT, a septal branch of the middle cardiac vein, and a po

205 CSD decreased sustained VT and ICD shock recurrence in patients with refractory

206 One-year freedom from sustained VT/ICD shock and ICD shock, transplant, and death were 5

207 predicted the combined endpoint of sustained VT/ICD shock recurrence, death, and transplantation.

208 oanatomic scar patterns related to sustained VT can distinguish exercise-induced arrhythmogenic remod

209 m (1-, 2-, and 3-year) survival, symptomatic VT control, and amiodarone use.

210 and recurrent ventricular tachyarrhythmias (VT).

211 during scar-related ventricular tachycardia (VT) ablation.

212 Recurrence of ventricular tachycardia (VT) after ablation in patients with previous myocardial

213 y ablation (RFA) of ventricular tachycardia (VT) can fail because of inaccessibility to the VT substr

214 r fibrillation (VF)/ventricular tachycardia (VT) cardiac arrest is unknown.

215 stained monomorphic ventricular tachycardia (VT) in LMNA cardiomyopathy.

216 er ablation (CA) of ventricular tachycardia (VT) in patients with cardiac sarcoidosis can be challeng

217 er ablation (CA) of ventricular tachycardia (VT) in patients with nonischemic dilated cardiomyopathy

218 Ventricular tachycardia (VT) is a major cause of sudden cardiac death.

219 atheter ablation of ventricular tachycardia (VT) is being increasingly performed; yet, there is often

220 the first event of ventricular tachycardia (VT) or fibrillation (VF).

221 Ventricular tachycardia (VT) radiofrequency ablation has been associated with red

222 In contrast to ventricular tachycardia (VT) that occurs in the setting of a structurally normal

223 their risk of death/ventricular tachycardia (VT), and (3) identify imaging-based covariates that pred

224 to treat recurrent ventricular tachycardia (VT).

225 ical remodeling and ventricular tachycardia (VT).

226 ) having documented ventricular tachycardia (VT)/ventricular fibrillation (VF) and Brugada syndrome-r

227 rienced ICD-treated ventricular tachycardia (VT)/ventricular fibrillation (VF).

228 f >/=1 ICD-treated ventricular tachycardias (VT)/ventricular fibrillation episode, or a recorded, sus

229 Target VT elevations in patients (P = 0.028 and 0.051 in cLBP a

230 In total, 147 AMF virtual taxa (VT) were detected, including 22 VT new to science.

231 biaryl 2-amides using variable-temperature (VT) NMR and exchange (EXSY) spectroscopy experiments.

232 rdial CA is effective in achieving long-term VT freedom in 69% of cases, with a substantial improveme

233 escribed by the term ventriculus terminalis (VT) or the fifth ventricle.

234 nation with red light effectively terminates VT in diseased, ChR2-expressing human hearts.

235 generally becomes increased more by fR than VT .

236 lectrode recording of SHR hearts showed that VT was initiated by early afterdepolarization (EAD)-medi

237 The VT MCD spectra of the enzymatic S = 2 Fe(IV) horizontal

238 The VT of a 49-y-old male HAB was 7.5 +/- 1.4 mL/cm(3) compa

239 The absolute PD of brain SUV and the VT had similar values.

240 h previously described horizontal cells, the VT cells have properties well suited to the visual navig

241 st VT zone, 509 of 590 (85% adjusted) in the VT zone, and 6 of 10 in the ventricular fibrillation zon

242 In patients, the VT of (11)C-erlotinib did not increase after intake of e

243 ) can fail because of inaccessibility to the VT substrate.

244 y included and classified depending on their VT substrate: (1) ischemic VT (IVT) and (2) nonischemic

245 mal, mild, moderate, and vision threatening (VT).

246 o supraventricular tachycardias converted to VT or ventricular fibrillation.

247 he increased susceptibility of SHR hearts to VT/VF, patch clamped isolated SHR ventricular myocytes d

248 1770 pace maps, 47 channels corresponded to VTs.

249 activation/entrainment mapping for tolerated VT and pacemapping/targeting of abnormal electrograms fo

250 ation self-motion, the vertical translation (VT) cells.

251 as significantly associated with ICD-treated VT/VF (adjusted hazard ratio, 3.98; 95% confidence inter

252 f NSVT were also associated with ICD-treated VT/VF (adjusted hazard ratio, 9.22; 95% confidence inter

253 ICD-treated VT/VF was associated with NSVT runs at a rate >200 beats

254 T were more highly predictive of ICD-treated VT/VF.

255 The regional distribution of elevated TSPO VT argues that the autoimmune/neuroinflammatory theories

256 Slightly lower elevations in TSPO VT (22%-29%) were present in other gray matter regions.

257 In OCD, TSPO VT was significantly elevated in these brain regions (me

258 The TSPO VT was measured in the dorsal caudate, orbitofrontal cor

259 To determine whether TSPO VT is elevated in the dorsal caudate, orbitofrontal cort

260 behaviors significantly correlated with TSPO VT in the orbitofrontal cortex (uncorrected Pearson corr

261 We compared vaccine type (VT; types 6, 11, 16, 18) prevalence according to vaccina

262 we evaluated the prevalence of vaccine-type (VT) HPV strains among young women in national data sets

263 ing strains were derived from vaccine types (VT) that had changed their capsule by recombination.

264 nts with structural heart disease undergoing VT ablation using the CARTOUNIVU module were prospective

265 METHODS AND NYHA II-IV patients undergoing VT radiofrequency ablation at 12 international centers w

266 ting of abnormal electrograms for unmappable VT.

267 Clinical variables, VT recurrence, and mortality were analyzed by NYHA IV st

268 ablation for scar-related right ventricular VT, 2 distinct scar distributions were identified: 1) sc

269 h nontraumatic OHCA, vascular access, and VF/VT anytime after >/=1 shock(s) were prospectively random

270 889 patients with OHCA, 3026 with initial VF/VT and 1063 with initial nonshockable-turned-shockable r

271 ecutive adult patients with refractory OH VF/VT cardiac arrest requiring ongoing cardiopulmonary resu

272 prevalent in patients with refractory OH VF/VT cardiac arrest who also met criteria for continuing r

273 asystole, pulseless electric activity, or VF/VT).

274 harge in patients experiencing refractory VF/VT cardiac arrest treated with a novel protocol of early

275 presenting with initial shock-refractory VF/VT were previously reported.

276 rom treatment of initial shock-refractory VF/VT with these drugs.

277 subsequently developing shock-refractory VF/VT.

278 lation/pulseless ventricular tachycardia [VF/VT]) during resuscitation.

279 e induced body ownership using visuotactile (VT) synchrony rather than visuomotor.

280 tted the data well, and distribution volume (VT) (mLcm(-3)) values ranged from 1.5 in the caudate to

281 e estimates of regional distribution volume (VT) and binding potential (BPND) with 120 min of scan da

282 Parametric distribution volume (VT) and influx rate (K1) were compared with those obtain

283 differences in SUV and distribution volume (VT) estimated with an arterial input function.

284 flammation and the TSPO distribution volume (VT) is an index of TSPO density.

285 The protective role of a small tidal volume (VT) has been established, whereas the added protection a

286 riety of changes in the depth (tidal volume, VT ) and number of breaths (respiratory frequency, fR ).

287 method were optimized, distribution volumes (VT) obtained with Logan graphic analysis, BFM, and SA al

288 method were optimized, distribution volumes (VT) obtained with Logan graphic analysis, BFM, and SA al

289 ing for calculation of distribution volumes (VT).

290 The outcome measure was VT/fP (VT is volume of distribution in region of interes

291 tatus and identified factors associated with VT prevalence.

292 ated, but generally were not associated with VT.

293 Compared with VT, differences in cortical Abeta load between aMCI and

294 ut function gave a VT highly consistent with VT in the kinetic model, which could be used for voxelwi

295 However, SUVRWM is better correlated with VT and more closely reflects VT differences between aMCI

296 Among the 58 (21%) patients with VT recurrence, CA still resulted in a significant reduct

297 al arrhythmogenic substrate in patients with VT with increasing precision.

298 the role of cardiac imaging in patients with VT.

299 Patients with VT/VF had significantly lower left ventricular ejection

300 ference region by comparing baseline VT with VT under full blocking conditions and comparing striatal

301 cardial walls compared with patients without VT/VF (anterior-strain, -7.7% versus -8.8%; P<0.001; lat